HLS Therapeutics Inc. (TSX:HLS)

Market Cap	146.67M
Revenue (ttm)	77.79M
Net Income (ttm)	-19.66M
Shares Out	31.27M
EPS (ttm)	-0.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,550
Average Volume	8,434
Open	4.630
Previous Close	4.720
Day's Range	4.600 - 4.690
52-Week Range	3.900 - 5.765
Beta	0.95
RSI	42.28
Earnings Date	Mar 12, 2026

About HLS Therapeutics

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders, central nervous system, and cardiovascular disease in Canada, the United States, and internationally. The company’s lead products include Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care de...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Craig Millian
• Employees: 92
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: HLS

Financial Performance

In 2024, HLS Therapeutics's revenue was $56.62 million, a decrease of -10.23% compared to the previous year's $63.07 million. Losses were -$19.66 million, -28.61% less than in 2023.

Financial numbers in USD